Skip to main content Back to Top
Advertisement

6/5/2019

Tobramycin Sulfate Injection

Products Affected - Description

    • Tobramycin Sulfate solution for injection, Akorn, 40 mg/mL, 2 mL vial, 25 count, NDC 17478-0114-02 - discontinued
    • Tobramycin Sulfate solution for injection, Akorn, 40 mg/mL, 30 mL vial, 1 count, NDC 17478-0114-30 - discontinued
    • Tobramycin Sulfate solution for injection, Teva, 40 mg/mL, 2 mL vial, 25 count, NDC 00703-9402-04 - discontinued
    • Tobramycin Sulfate solution for injection, Teva, 40 mg/mL, 30 mL vial, 1 count, NDC 00703-9416-01 - discontinued

Reason for the Shortage

    • Akorn discontinued tobramycin injection in late-2018.
    • Mylan Institutional refuses to provide availability information.
    • Pfizer had tobramycin injection on shortage due to manufacturing delays.
    • Teva discontinued tobramycin injection.

Available Products

    • Tobramycin Sulfate solution for injection, Baxter, 40 mg/mL, 2 mL vial, 25 count, NDC 36000-0244-25
    • Tobramycin Sulfate solution for injection, Baxter, 40 mg/mL, 30 mL vial, 1 count, NDC 36000-0242-01
    • Tobramycin Sulfate lyophilized powder for solution for injection, Fresenius Kabi, 1.2 gram, 50 mL preservative-free vial, 6 count, NDC 63323-0303-51
    • Tobramycin Sulfate solution for injection, Fresenius Kabi, 10 mg/mL, 2 mL vial, 25 count, NDC 63323-0305-02
    • Tobramycin Sulfate solution for injection, Fresenius Kabi, 40 mg/mL, 2 mL vial, 25 count, NDC 63323-0306-02
    • Tobramycin Sulfate solution for injection, Fresenius Kabi, 40 mg/mL, 30 mL vial, 10 count, NDC 63323-0306-30
    • Tobramycin Sulfate solution for injection, Fresenius Kabi, 40 mg/mL, 50 mL vial, 1 count, NDC 63323-0307-51
    • Tobramycin Sulfate solution for injection, Pfizer, 40 mg/mL, 2 mL vial, 25 count, NDC 00409-3578-01
    • Tobramycin Sulfate lyophilized powder for solution for injection, X-Gen, 1.2 gram, 50 mL preservative-free vial, 1 count, NDC 39822-0412-01
    • Tobramycin Sulfate lyophilized powder for solution for injection, X-Gen, 1.2 gram, 50 mL preservative-free vial, 6 count, NDC 39822-0412-06

Estimated Resupply Dates

    • All marketed presentations that we are able to get information on are available.

Updated

Updated June 5, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 28, 2010 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins